...
AZNMEGA

AstraZeneca PLC

HealthcareDrug Manufacturers - General
$208.45
$0.05(+2.19%)
52W$91.44
$212.71
FinancialsValuationvs LLY
Updated Mar 1, 12:00 AM
RSI59
RS Rating81/99
Beta0.27
Volatility111%
F-Score8/9
Mkt Cap$323.2B
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

AstraZeneca PLC is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings growth of 54% provides fundamental context to the price action. Investors should exercise caution due to high volatility (111% annualized), which requires wider risk management.

Relative Strength
81
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
0.27
vs S&P 500
LOW VOL
52W Position
96%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$190.19
50 SMA > 100 SMA$182.00
100 SMA > 150 SMA$173.07
150 SMA > 200 SMA$165.34

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$199.21+4.64%ABOVE
50 SMA$190.19+9.60%ABOVE
100 SMA$182.00+14.53%ABOVE
150 SMA$173.07+20.44%ABOVE
200 SMA$165.34+26.07%ABOVE

Price Performance

1D+2.2%
1W+1.7%
1M+11.0%
3M+13.4%
6M+31.8%
YTD+14.1%
1Y+38.5%
3Y+17.3%
52-Week Trading Range96% from low
$208.45
52W Low$91.44
52W High$212.71

Technical Indicators

RSI (14)NEUTRAL
59.1
305070
VCP ScoreCOOL
5/10
Base depth: 58.2%

Risk Profile

Beta
0.27
52W Vol
111%
ATR
$4.98
Max DD (1Y)
-51%

Volume Analysis

Today
2.00M
50D Avg
1.48M
Vol Ratio
1.35x
Liquidity
VERY LIQUID

Earnings Momentum

Q1'25+34%
$0.94
Q2'25+27%
$0.79
Q3'25+76%
$0.81
Q4'25+54%
$0.74
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+9.05%
5 Years:+17.15%
3 Years:+9.82%
TTM:+8.63%

Compounded Profit Growth

10 Years:+11.31%
5 Years:+21.80%
3 Years:+45.57%
TTM:+45.13%

Stock Price CAGR

10 Years:+13.94%
5 Years:+16.31%
3 Years:+17.28%
1 Year:+38.54%

Return on Equity

10Y Avg:14.8%
5Y Avg:13.0%
3Y Avg:18.7%
Last Year:21.0%

Key Metrics

Market Cap$323.2B
Gross Margin81.9%
Net Margin17.5%
Piotroski F-Score8/9

More AZN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

AZN vs LLYLLYJNJBMYCELG-RI

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 81 meansAZN outperformed 81% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.27 means 73% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 8/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is AZN in an uptrend right now?

AZN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AZN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is AZN overbought or oversold?

AZN's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.

Is AZN outperforming the market?

AZN has a Relative Strength (RS) Rating of 81 out of 99. Yes, AZN is a market leader, outperforming 81% of all stocks over the past 12 months.

Where is AZN in its 52-week range?

AZN is trading at $208.45, which is 98% of its 52-week high ($212.71) and 96% above its 52-week low ($91.44).

How volatile is AZN?

AZN has a Beta of 0.27 and 52-week volatility of 111%. It's less volatile than the S&P 500 - generally more stable.